Download PDF
Dtsch Med Wochenschr 2014; 139(23): 1213-1215
DOI: 10.1055/s-0034-1370064
Hämatologie & Onkologie | Commentary
Hämatologie
© Georg Thieme Verlag KG Stuttgart · New York

Therapie peripherer T-Zell-Lymphome

Treatment of peripheral T-cell lymphoma
G. G. Wulf
1   Hämatologie und Medizinische Onkologie, Universitätsmedizin Göttingen
,
L. Trümper
1   Hämatologie und Medizinische Onkologie, Universitätsmedizin Göttingen
› Author Affiliations
Further Information

Publication History

Publication Date:
27 May 2014 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

periphere T-Zell-Lymphome - PTCL - NK/T-Zell-Lymphome vom nasalen Typ - großzelliges anaplastisches Lymphom - ALCL

Keywords

peripheral T-cell lymphoma - PTCL - NK/T-cell lymphoma nasal type - anaplastic large cell lymphoma - ALCL
 

  • Literatur

  • 1 Coiffier B, Pro B, Prince HM et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30: 631-636
    CrossrefPubMedGoogle Scholar
  • 2 D'Amore F, Relander T, Lauritzsen GF et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093-3099
    CrossrefPubMedGoogle Scholar
  • 3 Damaj G, Gressin R, Bouabdallah K et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013; 31: 104-110
    CrossrefPubMedGoogle Scholar
  • 4 Dodero A, Spina F, Narni F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520-526
    CrossrefPubMedGoogle Scholar
  • 5 Foss F. Hematology: relapsed and refractory PTCL – into the therapeutic abyss. Nat Rev Clin Oncol 2011; 8: 321-322
    PubMedGoogle Scholar
  • 6 Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand?. Semin Hematol 2014; 51: 5-16
    CrossrefPubMedGoogle Scholar
  • 7 Jaccard A, Gachard N, Marin B et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011; 117: 1834-1839
    CrossrefPubMedGoogle Scholar
  • 8 Jacobsen ED, Kim HT, Ho VT et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011; 22: 1608-1613
    CrossrefPubMedGoogle Scholar
  • 9 Le Deley MC, Rosolen A, Williams DM et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010; 28: 3987-3993
    CrossrefPubMedGoogle Scholar
  • 10 Le GS, Milpied N, Buzyn A et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264-2271
    CrossrefPubMedGoogle Scholar
  • 11 Mak V, Hamm J, Chhanabhai M et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013; 31: 1970-1976
    CrossrefPubMedGoogle Scholar
  • 12 Morschhauser F, Fitoussi O, Haioun C et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013; 49: 2869-2876
    CrossrefPubMedGoogle Scholar
  • 13 Mussolin L, Damm-Welk C, Pillon M et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia 2013; 27: 416-422
    CrossrefPubMedGoogle Scholar
  • 14 O'Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182-1189
    CrossrefPubMedGoogle Scholar
  • 15 Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190-2196
    CrossrefPubMedGoogle Scholar
  • 16 Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418-3425
    CrossrefPubMedGoogle Scholar
  • 17 Sibon D, Fournier M, Briere J et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol 2012; 30: 3939-3946
    CrossrefPubMedGoogle Scholar
  • 18 Suzuki R. NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm. Curr Oncol Rep 2012; 14: 395-402
    CrossrefPubMedGoogle Scholar
  • 19 Suzuki R. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma. Semin Hematol 2014; 51: 42-51
    CrossrefPubMedGoogle Scholar
  • 20 Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-4130
    CrossrefPubMedGoogle Scholar
  • 21 Yamaguchi M, Kwong YL, Kim WS et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011; 29: 4410-4416
    CrossrefPubMedGoogle Scholar
  • 22 Yamaguchi M. Current and future management of NK/T-cell lymphoma based on clinical trials. Int J Hematol 2012; 96: 562-571
    CrossrefPubMedGoogle Scholar